SHR 0534Alternative Names: SHR0534
Latest Information Update: 02 Jan 2017
Price : $50
At a glance
- Originator Jiangsu Hengrui Medicine Co.
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Type 2 diabetes mellitus
Most Recent Events
- 01 Jan 2016 Jiangsu HengRui Medicine Co completes a phase I trial in Healthy volunteers in China (PO) (NCT02750553)